Human Growth Hormone is an injectable hormone that can be administered subcutaneously or intramuscularly. When injected subcutaneously, HGH carries a bioavailability of approximately seventy-five percent. When injected intramuscularly, HGH carries a bioavailability of approximately sixty-three percent. The mode of administration will also affect the half-life of the Somatropin hormone. When injected subcutaneously, it will carry a half-life of approximately hours. When injected intramuscularly, it will carry a half-life of approximately hours. While this is a rather short half-life regardless of the mode of administration, keep in mind the total effects far outlast these numbers due to the pronounced and significant increases in IGF-1 production that stretch far past the twenty-four hour mark.
It is suggested that a continued position of equipoise be taken regarding neonatal resuscitation with the cord attached. Until further evidence is available, a reasonable approach is to perform an initial evaluation with the cord attached. If clinical signs indicate a need for resuscitation (ineffective respiratory effort or bradycardia despite gentle stimulation), the cord should be clamped and respiratory support initiated as per NRP guidelines. Alternatively, resuscitation with the cord intact may be considered as part of a clinical trial, or if institutional policy, staff training and birth set-up support this practice.